The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Settlement reached with the FHFA re US RMBS claims

12 Jul 2017 13:34

RNS Number : 8869K
Royal Bank of Scotland Group PLC
12 July 2017
 

The Royal Bank of Scotland Group plc

 

Settlement reached with the Federal Housing Finance Agency regarding US RMBS claims

 

12 July 2017

 

 

The Royal Bank of Scotland Group plc (together with its subsidiaries, "RBS") has reached a settlement with the Federal Housing Finance Agency ("FHFA") as conservator of Fannie Mae and Freddie Mac, to resolve claims by FHFA in relation to RBS's issuance and underwriting of approximately US$32 billion (£25 billion) of residential mortgage-backed securities ("RMBS") in the US.  As part of the settlement, FHFA's outstanding litigation against RBS will be withdrawn. 

Ross McEwan, RBS CEO, said:

 

"Today's announcement is an important step forward in resolving one of the most significant legacy matters facing RBS and is further evidence of the determination of the bank's leadership to put our remaining issues behind us.

 

"This settlement is a stark reminder of what happened to this bank before the financial crisis, and the heavy price paid for its pursuit of global ambitions."

 

Financial Impact of the FHFA settlement

 

Under the settlement, RBS will pay FHFA US$5.5 billion (£4.2 billion), of which US$754 million (£581 million) will be reimbursed to RBS under indemnification agreements with third parties.

 

The cost to RBS (net of the indemnity mentioned above) of US$4.75 billion (£3.65 billion) is largely covered by existing provisions. An incremental charge of US$196 million (£151 million) will be recorded in the RBS Q2 2017 results which will be published on 4 August 2017.

 

As at end Q1 2017, RBS held a provision of US$8.3 billion (£6.6 billion) against RMBS, of which $4.55 billion (£3.6 billion) related to FHFA and the remainder principally relates to a number of the matters described below.

 

 

Ongoing Legacy Inquiries and Litigation

 

RBS is one of 17 financial institutions to have settled RMBS claims filed by FHFA. Following this settlement, RBS's unresolved RMBS litigation matters involve the issuance of less than US $1 billion of RMBS issued primarily from 2005 to 2007, assuming court approval of an agreed and provided for settlement. This unresolved amount does not include the FHFA case involving RMBS issued by Nomura, which RBS estimates its net exposure as approximately US $383 million (£295 million) and intends to pursue indemnification for. This net exposure was also included within RMBS related provisions as at Q1 2017.

 

As previously disclosed, RBS continues to cooperate with RMBS related investigations and proceedings (both formal and informal) by federal and state governmental law enforcement and other agencies including the US Department of Justice ("DOJ") and various other members of the RMBS Working Group of the US Financial Fraud Enforcement Task Force. The duration and outcome of these investigations, including in particular the DOJ's civil and criminal investigations, and other RMBS litigation matters remain uncertain, including in respect of whether settlements for all or any of such matters may be reached.

 

RBS is not making any other adjustments to existing provisions relating to RMBS matters as a result of today's settlement but continues to advise that further substantial provisions and costs may be recognised and, depending upon the final outcomes, other adverse consequences may occur. Please see RBS's 2016 Annual Report and Accounts for further information on these outstanding investigations and litigation matters.

 

Investor call

 

Ewen Stevenson (Chief Financial Officer) will host a conference call for investors and analysts at 14.30 BST. A replay of the call will be made available shortly afterwards. Only items relating to the above announcement will be discussed on the call; there will be no references and discussion relating to other matters and the Q2 2017 results.

 

Dial-in details:

UK: 0800 694 8082

International: +44 (0) 1452 568 172

US: +1 866 966 8024

Conference ID: 54462050

 

Replay details:

UK FreeCall: 0800 953 1533

Std International: +44 (0)1452 550 000

USA FreeCall: +1 (866) 247 4222

Conference ID: 54462050

 

For further information, please contact:

 

RBS Investor Relations

+44 (0) 20 7672 1758

 

RBS Media Relations

+44 (0) 131 523 4205

 

Forward Looking StatementsThis announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including those related to RBS and its subsidiaries' regulatory capital position, risk-weighted assets, impairment losses and credit exposures under certain specified scenarios. In addition, forward-looking statements may include, without limitation, statements typically containing words such as "intends", "expects", "anticipates", "targets", "plans", "estimates" and words of similar import. These statements concern or may affect future matters, such as RBS's future economic results, business and capital plans and current strategies. Forward-looking statements are subject to a number of risks and uncertainties that might cause actual results and performance to differ materially from any expected future results or performance expressed or implied by the forward-looking statements. Factors that could cause or contribute to differences in current expectations include, but are not limited to, legislative, fiscal and regulatory developments, competitive conditions, technological developments, exchange rate fluctuations and general economic conditions. These and other factors, risks and uncertainties that may impact any forward-looking statement or RBS's actual results are discussed in RBS's UK annual report and accounts and interim reports and materials filed with, or furnished to, the US Securities and Exchange Commission, including, but not limited to, RBS's Reports on Form 6-K and most recent Annual Report on Form 20-F. The forward-looking statements contained in this announcement speak only as of the date of this announcement and RBS does not assume or undertake any obligation or responsibility to update any of the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.

 

MAR

 

This announcement contains information that qualified or may have qualified as inside information for the

purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 (MAR). For the purposes of MAR and Article 2 of Commission Implementing Regulation (EU) 2016/1055, this announcement is made by Matt Waymark, Head of Investor Relations for The Royal Bank of Scotland Group.

 

LEI - The Royal Bank of Scotland Group plc - 2138005O9XJIJN4JPN90

LEI - The Royal Bank of Scotland plc - RR3QWICWWIPCS8A4S074

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGGUGWMUPMGPP
Date   Source Headline
17th Mar 20205:24 pmRNSDirectorate Change
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
17th Mar 20208:30 amRNSMorgan Stanley European Financials Conference
16th Mar 20205:14 pmRNSNatWest Markets N.V. 2019 ARA
10th Mar 20204:51 pmRNSDirector/PDMR Shareholding
2nd Mar 20202:34 pmRNSDirector/PDMR Shareholding
28th Feb 20204:29 pmRNSCorrection of Dividend Declaration
28th Feb 20201:58 pmRNSTotal Voting Rights and Capital
28th Feb 20207:00 amRNSFiling of Annual Report on Form 20-F with US SEC
27th Feb 20209:55 amRNSBlock Listing Cancellation
24th Feb 202012:40 pmRNSDividend Declaration
20th Feb 20204:10 pmRNSHolding(s) in Company
14th Feb 20203:58 pmRNSRBSG ENTM Publication of Suppl.Prospcts
14th Feb 20207:01 amRNSAnnual Financial Report
14th Feb 20207:00 amRNSFinal Results
31st Jan 20202:12 pmRNSTotal Voting Rights and Capital
30th Jan 20203:57 pmRNSDirector/PDMR Shareholding
16th Jan 20202:08 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Jan 20201:58 pmRNSForm 8.3 - Accesso Technology Group plc
31st Dec 20191:10 pmRNSDirector/PDMR Shareholding
31st Dec 201911:20 amRNSTotal Voting Rights and Capital
30th Dec 20193:02 pmRNSForm 8.3 - Accesso Technology Group plc
20th Dec 20197:00 amRNSPublication of Suppl.Prospcts replacement
19th Dec 20195:40 pmRNSPublication of Suppl.Prospcts
19th Dec 20197:00 amRNSNatWest Markets Change in Executive Directors
16th Dec 20195:47 pmRNS2019 Bank of England stress test results
4th Dec 201912:34 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Dec 20195:34 pmRNSPublication of Suppl.Prospcts
29th Nov 20192:20 pmRNSDirector/PDMR Shareholding
29th Nov 20191:28 pmRNSAnnouncement of NatWest Markets N.V. Transfer
29th Nov 201912:01 pmRNSTotal Voting Rights and Capital
27th Nov 201911:56 amRNSDividend Declaration
21st Nov 20196:26 pmRNSPublication of a Prospectus
21st Nov 201910:45 amRNSReduction in Pillar 2A capital requirements
14th Nov 201911:23 amRNSPublication of Final Terms
13th Nov 20193:00 pmRNSForm 8.3 - Accesso Technology Group plc
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
1st Nov 20194:12 pmRNSDirector/PDMR Shareholding
31st Oct 20193:30 pmRNSDirector/PDMR Shareholding
31st Oct 20192:08 pmRNSTotal Voting Rights and Capital
30th Oct 20199:38 amRNSRBSG pricing of US$750mn of Subordinated Notes
25th Oct 20195:22 pmRNSPublication of Suppl.Prospcts
24th Oct 20197:00 amRNSQ3 Interim Management Statement
16th Oct 20192:54 pmRNSForm 8.3 - Accesso Technology Group plc
8th Oct 201911:35 amRNSBlock Listing Six Monthly Return
3rd Oct 20191:08 pmRNSPublication of Final Terms
1st Oct 20195:29 pmRNSDirector/PDMR Shareholding
30th Sep 20193:28 pmRNSTotal Voting Rights
24th Sep 20198:30 amRNSBank of America Merrill Lynch Annual Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.